Liposomes targeted to MHC-restricted antigen improve drug delivery and antimelanoma response

References

• MaioMMelanoma as a model tumour for immunooncologyAnn Oncol201223suppl 8viii10viii1422918922
   PubMedGoogle Scholar
• Cancer.NetMelanoma: Statistics Available from: http://www.cancer.net/cancer-types/melanoma/statisticsAccessed June 1, 2014
   Google Scholar
• ArisMBarrioMMCombining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatmentFront Immunol2015624625709607
   PubMedGoogle Scholar
• FucàGde BraudFDi NicolaMImmunotherapy-based combinations: an updateCurr Opin Oncol201830534535129994900
   PubMedGoogle Scholar
• FestinoLVanellaVTrojanielloCAsciertoPASelecting immuno-oncology-based drug combinations – what should we be considering?Expert Rev Clin Pharmacol2018111097198530169990
   PubMed Web of Science ®Google Scholar
• MaruyamaKPEG-immunoliposomeBiosci Rep200222225126612428903
   PubMed Web of Science ®Google Scholar
• AllenTMLigand-targeted therapeutics in anticancer therapyNat Rev Cancer200221075076312360278
   PubMed Web of Science ®Google Scholar
• SunXYanXJacobsonOImproved tumor uptake by optimizing liposome based RES blockade strategyTheranostics20177231932828042337
   PubMed Web of Science ®Google Scholar
• DeshpandePPBiswasSTorchilinVPCurrent trends in the use of liposomes for tumor targetingNanomedicine2013891509152823914966
   PubMed Web of Science ®Google Scholar
• IdenDLAllenTMIn vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approachBiochim Biophys Acta20011513220721611470092
   PubMed Web of Science ®Google Scholar
• ShmeedaHTzemachDMakLGabizonAHER2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passageJ Control Release2009136215516019331844
   PubMedGoogle Scholar
• DeshpandePJhaveriAPattniBBiswasSTorchilinVTransferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancerDrug Deliv201825151753229433357
   PubMed Web of Science ®Google Scholar
• SugiyamaIKaihatsuKSomaYKatoNSadzukaYDual-effect liposomes with increased antitumor effects against 67-kDa laminin receptor-overexpressing tumor cellsInt J Pharm20185411–220621329486285
   PubMedGoogle Scholar
• LuLDingYZhangYAntibody-modified liposomes for tumor-targeting delivery of timosaponin AIIIInt J Nanomedicine2018131927194429636610
   PubMed Web of Science ®Google Scholar
• KunertAStraetemansTGoversCTCR-Engineered T cells meet new challenges to treat solid tumors: choice of antigen, T cell fitness, and sensitization of tumor milieuFront Immunol2013411623355837
   PubMedGoogle Scholar
• CouliePGvan den EyndeBJvan der BruggenPBoonTTumour antigens recognized by T lymphocytes: at the core of cancer immunotherapyNat Rev Cancer201414213514624457417
   PubMed Web of Science ®Google Scholar
• BarrowCBrowningJMacgregorDTumor antigen expression in melanoma varies according to antigen and stageClin Cancer Res2006123 Pt 176477116467087
   PubMed Web of Science ®Google Scholar
• BrasseurFRimoldiDLiénardDExpression of MAGE genes in primary and metastatic cutaneous melanomaInt J Cancer19956333753807591235
   PubMedGoogle Scholar
• CaballeroOLChenYTCancer/testis (CT) antigens: potential targets for immunotherapyCancer Sci2009100112014202119719775
   PubMed Web of Science ®Google Scholar
• PavlinkovaGColcherDBoothBJGoelAWittelUABatraSKEffects of humanization and gene shuffling on immunogenicity and antigen binding of anti-TAG-72 single-chain FvsInt J Cancer200194571772611745468
   PubMedGoogle Scholar
• ChamesPHuftonSECouliePGUchanska-ZieglerBHoogenboomHRDirect selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab libraryProc Natl Acad Sci200097147969797410884427
   PubMed Web of Science ®Google Scholar
• WillemsenRADebetsRHartEHoogenboomHRBolhuisRLChamesPA phage display selected Fab fragment with MHC class I- restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytesGene Ther20018211601160811894998
   PubMedGoogle Scholar
• ChamesPWillemsenRARojasGTCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activityJ Immunol200216921110111812097420
   PubMedGoogle Scholar
• SaeedMvan BrakelMZalbaSTargeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibodyInt J Nanomedicine20161195597527022262
   PubMed Web of Science ®Google Scholar
• AmselemSGabizonABarenholzYOptimization and upscaling of doxorubicin-containing liposomes for clinical useJ Pharm Sci19907912104510522079648
   PubMed Web of Science ®Google Scholar
• KhanDRWebbMNCadotteTHGavetteMNUse of targeted liposome-based chemotherapeutics to treat breast cancerBreast Cancer20159Suppl 215
   PubMedGoogle Scholar
• MohammadiZAAghamiriSFZarrabiATalaieMRLiposomal doxorubicin delivery systems: effects of formulation and processing parameters on drug loading and release behaviorCurr Drug Deliv20161371065107026708673
   PubMed Web of Science ®Google Scholar
• BarenholzYBarenholzYDoxil® – the first FDA-approved nano-drug: lessons learnedJ Control Release2012160211713422484195
   PubMed Web of Science ®Google Scholar
• HochuliELarge-scale chromatography of recombinant proteinsJ Chromatogr19884442933023060478
   PubMed Web of Science ®Google Scholar
• MesserschmidtSKEBeuttlerJRothdienerMImmunoliposomesKontermannRDubelSAntibody Engineering2New YorkSpringer2010401428
   Google Scholar
• AbrahamSAWaterhouseDNMayerLDCullisPRMaddenTDBallyMBThe liposomal formulation of doxorubicinMethods Enzymol2005391719715721375
   PubMed Web of Science ®Google Scholar
• HaranGCohenRBarLKBarenholzYTransmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak basesBiochim Biophys Acta1993115122012158373796
   PubMed Web of Science ®Google Scholar
• LiLTen HagenTLHossannMMild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacyJ Control Release2013168214215023524188
   PubMed Web of Science ®Google Scholar
• RouserGFkeischerSYamamotoATwo dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spotsLipids1970554944965483450
   PubMed Web of Science ®Google Scholar
• DichevaBMTen HagenTLSeynhaeveALAminMEggermontAMKoningGAEnhanced specificity and drug delivery in tumors by cRGD-anchoring thermosensitive liposomesPharm Res201532123862387626202516
   PubMed Web of Science ®Google Scholar
• KontermannREImmunoliposomes for cancer therapyCurr Opin Mol Ther200681394516506524
   PubMedGoogle Scholar
• RügerRMüllerDFahrAKontermannREGeneration of immunoliposomes using recombinant single-chain Fv fragments bound to Ni-NTA-liposomesJ Drug Target200513739940616308208
   PubMed Web of Science ®Google Scholar
• RothdienerMBeuttlerJMesserschmidtSKKontermannREAntibody targeting of nanoparticles to tumor-specific receptors: immunoliposomesMethods Mol Biol201062429530820217604
   PubMedGoogle Scholar
• PetersonRCApplication of Lowry protein determination to influenza vaccineJ Pharm Sci19695811411425765826
   PubMedGoogle Scholar
• WillemsenRARonteltapCChamesPDebetsRBolhuisRLT cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine productionJ Immunol2005174127853785815944290
   PubMedGoogle Scholar
• SchaftNLankiewiczBDrexhageJT cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma productionInt Immunol200618459160116507598
   PubMedGoogle Scholar
• RoszikJSebestyénZGoversCT-cell synapse formation depends on antigen recognition but not CD3 interaction: studies with TCR: ζ, a candidate transgene for TCR gene therapyEur J Immunol20114151288129721469084
   PubMedGoogle Scholar
• SebestyénZSchootenESalsTHuman TCR that incorporate CD3 induce highly preferred pairing between TCR and chains following gene transferJ Immunol2008180117736774618490778
   PubMedGoogle Scholar
• DichevaBMTen HagenTLSchipperDTargeted and heat-triggered doxorubicin delivery to tumors by dual targeted cationic thermosensitive liposomesJ Control Release2014195374825176578
   PubMed Web of Science ®Google Scholar
• SkehanPStorengRScudieroDNew colorimetric cytotoxicity assay for anticancer-drug screeningJ Natl Cancer Inst19908213110711122359136
   PubMed Web of Science ®Google Scholar
• HovingSSeynhaeveALvan TielSTEggermontAMTen HagenTLAddition of low-dose tumor necrosis factor-alpha to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing ratsAnticancer Drugs200516666767415930896
   PubMedGoogle Scholar
• SeynhaeveALBHovingSSchipperDTumor necrosis factor α mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor responseCancer Res200767199455946217909055
   PubMed Web of Science ®Google Scholar
• ShiCGuoDXiaoKWangXWangLLuoJA drug-specific nanocarrier design for efficient anticancer therapyNat Commun201561744926158623
   PubMedGoogle Scholar
• HiokiAWakasugiAKawanoKHattoriYMaitaniYDevelopment of an in vitro drug release assay of PEGylated liposome using bovine serum albumin and high temperatureBiol Pharm Bull20103391466147020823558
   PubMedGoogle Scholar
• LuoRLiYHeMDistinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulationsInt J Pharm20175191–211028063903
   PubMedGoogle Scholar
• SeynhaeveALBDichevaBMHovingSKoningGATen HagenTLMIntact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: evaluated by in vitro/in vivo live cell imagingJ Control Release2013172133034024012486
   PubMed Web of Science ®Google Scholar
• ChengWWAllenTMThe use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatmentExpert Opin Drug Deliv20107446147820331354
   PubMed Web of Science ®Google Scholar
• TernantDPaintaudGPharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteinsExpert Opin Biol Ther20055Suppl 1S37S4716187939
   PubMedGoogle Scholar
• BaumPMüllerDRügerRKontermannRESingle-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cellsJ Drug Target200715639940617613658
   PubMed Web of Science ®Google Scholar
• ThorpeSJTurnerCHeathAClonal analysis of a human antimouse antibody (HAMA) responseScand J Immunol2003571859212542802
   PubMedGoogle Scholar
• GabizonAShmeedaHHorowitzATZalipskySTumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugatesAdv Drug Deliv Rev20045681177119215094214
   PubMed Web of Science ®Google Scholar
• ChengWWAllenTMTargeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab’ fragments and single chain FvJ Control Release20081261505818068849
   PubMed Web of Science ®Google Scholar
• AminMBadieeAJaafariMRImprovement of pharmacokinetic and antitumor activity of pegylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomasInt J Pharm2013458232433324148663
   PubMedGoogle Scholar
• MiaoLNewbyJMLinCMThe binding site barrier elicited by tumor-associated fibroblasts interferes disposition of nanoparticles in stroma-vessel type tumorsACS Nano201610109243925827666558
   PubMed Web of Science ®Google Scholar
• SagaTNeumannRDHeyaTTargeting cancer micrometastases with monoclonal antibodies: a binding-site barrierProc Natl Acad Sci U S A19959219899990037568060
   PubMed Web of Science ®Google Scholar
• SapraPAllenTMInternalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugsCancer Res200262247190719412499256
   PubMed Web of Science ®Google Scholar
• NielsenUBKirpotinDBPickeringEMTherapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosisBiochim Biophys Acta200215911–310911812183061
   PubMed Web of Science ®Google Scholar
• ManzoorAALindnerLHLandonCDOvercoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumorsCancer Res201272215566557522952218
   PubMed Web of Science ®Google Scholar
• BertrandNWuJXuXKamalyNFarokhzadOCCancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biologyAdv Drug Deliv Rev20146622524270007
   PubMed Web of Science ®Google Scholar
• PrabhakarUMaedaHJainRKChallenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncologyCancer Res20137382412241723423979
   PubMed Web of Science ®Google Scholar